Thrombosis UK | Become a Fundraiser and support Thrombosis UK. Together we can make a difference

The GARFIELD-VTE Registry's First-ever Results

Presented at the ISTH 2017 Congress Shed Light on a Wide Heterogeneity of VTE Patients Across the Globe, their Treatment and Outcomes.

The first results from the Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE) were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2017, in Berlin, Germany this week, providing a contemporary picture of VTE management worldwide.

GARFIELD-VTE is a prospective, multicentre, observational study of patients requiring treatment for acute VTE. The registry enrolled more than 10,000 patients with acute VTE [deep vein thrombosis (DVT) and pulmonary embolism (PE)] from across 415 sites in 28 countries between May 2014 and January 2017. Study sites reflect the diversity of care settings in each country, including hospital, outpatient and community settings, making this study uniquely placed to provide data on several subsets of VTE patients, including those with recurrent VTE, post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension.

The aim of this global registry is to follow patients for at least three years and to observe patients' management according to local practices and to record clinical, patient-reported and economic outcomes. The first data from GARFIELD-VTE offer fresh insights into the clinical characteristics, treatment patterns and outcomes of VTE patients, including those with cancer.

Read the Full Article